BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 27170515)

  • 1. Carvacrol Inhibits Osteoclastogenesis and Negatively Regulates the Survival of Mature Osteoclasts.
    Deepak V; Kasonga A; Kruger MC; Coetzee M
    Biol Pharm Bull; 2016 Jul; 39(7):1150-8. PubMed ID: 27170515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic acid phenethyl ester, an active component of honeybee propolis attenuates osteoclastogenesis and bone resorption via the suppression of RANKL-induced NF-kappaB and NFAT activity.
    Ang ES; Pavlos NJ; Chai LY; Qi M; Cheng TS; Steer JH; Joyce DA; Zheng MH; Xu J
    J Cell Physiol; 2009 Dec; 221(3):642-9. PubMed ID: 19681045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calebin A downregulates osteoclastogenesis through suppression of RANKL signalling.
    Tyagi AK; Prasad S; Majeed M; Aggarwal BB
    Arch Biochem Biophys; 2016 Mar; 593():80-9. PubMed ID: 26874195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.
    Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M
    J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palmitoleic Acid Inhibits RANKL-Induced Osteoclastogenesis and Bone Resorption by Suppressing NF-κB and MAPK Signalling Pathways.
    van Heerden B; Kasonga A; Kruger MC; Coetzee M
    Nutrients; 2017 Apr; 9(5):. PubMed ID: 28452958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sesquiterpene lactone parthenolide blocks lipopolysaccharide-induced osteolysis through the suppression of NF-kappaB activity.
    Yip KH; Zheng MH; Feng HT; Steer JH; Joyce DA; Xu J
    J Bone Miner Res; 2004 Nov; 19(11):1905-16. PubMed ID: 15476591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
    Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
    Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation.
    Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J
    J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand through modulation of NF-kappaB pathway.
    Ahn KS; Sethi G; Chaturvedi MM; Aggarwal BB
    Int J Cancer; 2008 Oct; 123(8):1733-40. PubMed ID: 18688862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid receptor-2 selective antagonist negatively regulates receptor activator of nuclear factor kappa B ligand mediated osteoclastogenesis.
    Geng DC; Xu YZ; Yang HL; Zhu GM; Wang XB; Zhu XS
    Chin Med J (Engl); 2011 Feb; 124(4):586-90. PubMed ID: 21362286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-κB pathway inhibition by anthrocyclic glycoside aloin is key event in preventing osteoclastogenesis in RAW264.7 cells.
    Pengjam Y; Madhyastha H; Madhyastha R; Yamaguchi Y; Nakajima Y; Maruyama M
    Phytomedicine; 2016 Apr; 23(4):417-28. PubMed ID: 27002412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herbacetin inhibits RANKL-mediated osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Li L; Sapkota M; Kim SW; Soh Y
    Eur J Pharmacol; 2016 Apr; 777():17-25. PubMed ID: 26923730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways.
    Hu JP; Nishishita K; Sakai E; Yoshida H; Kato Y; Tsukuba T; Okamoto K
    Eur J Pharmacol; 2008 Feb; 580(1-2):70-9. PubMed ID: 18083161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
    Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
    Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SC-514, a selective inhibitor of IKKβ attenuates RANKL-induced osteoclastogenesis and NF-κB activation.
    Liu Q; Wu H; Chim SM; Zhou L; Zhao J; Feng H; Wei Q; Wang Q; Zheng MH; Tan RX; Gu Q; Xu J; Pavlos N; Tickner J; Xu J
    Biochem Pharmacol; 2013 Dec; 86(12):1775-83. PubMed ID: 24091016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decoy receptor 3 suppresses RANKL-induced osteoclastogenesis via down-regulating NFATc1 and enhancing cell apoptosis.
    Cheng CP; Sheu MJ; Sytwu HK; Chang DM
    Rheumatology (Oxford); 2013 Apr; 52(4):609-22. PubMed ID: 23221330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H; Murakami A; Aggarwal BB
    Mol Cancer Res; 2006 Apr; 4(4):275-81. PubMed ID: 16603641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.